JP2020510622A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020510622A5 JP2020510622A5 JP2019531127A JP2019531127A JP2020510622A5 JP 2020510622 A5 JP2020510622 A5 JP 2020510622A5 JP 2019531127 A JP2019531127 A JP 2019531127A JP 2019531127 A JP2019531127 A JP 2019531127A JP 2020510622 A5 JP2020510622 A5 JP 2020510622A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- composition
- glucan
- composition according
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 76
- 229920002498 Beta-glucan Polymers 0.000 claims description 58
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 34
- 239000008103 glucose Substances 0.000 claims description 34
- 239000000178 monomer Substances 0.000 claims description 34
- 206010028980 Neoplasm Diseases 0.000 claims description 15
- 201000011510 cancer Diseases 0.000 claims description 14
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 4
- -1 EGFRVIII Proteins 0.000 claims description 4
- 229920001503 Glucan Polymers 0.000 claims description 4
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 4
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 4
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 4
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims description 4
- 101710184277 Insulin-like growth factor 1 receptor Proteins 0.000 claims description 4
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 claims description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 102100024217 CAMPATH-1 antigen Human genes 0.000 claims description 2
- 108010065524 CD52 Antigen Proteins 0.000 claims description 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims description 2
- 102100023126 Cell surface glycoprotein MUC18 Human genes 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 2
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims description 2
- 101000623903 Homo sapiens Cell surface glycoprotein MUC18 Proteins 0.000 claims description 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 101100346932 Mus musculus Muc1 gene Proteins 0.000 claims description 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims description 2
- 206010061934 Salivary gland cancer Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 claims description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 2
- 230000003321 amplification Effects 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 2
- 201000005787 hematologic cancer Diseases 0.000 claims description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 2
- 230000002018 overexpression Effects 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 229960000575 trastuzumab Drugs 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 17
- 0 C[*-]*(*)O[C@@]([C@]([C@]1O)O)O[C@](CC(*)(*)O[C@@]([C@@]([C@]2O)O)O[C@](CO)[C@]2O)[C@]1O Chemical compound C[*-]*(*)O[C@@]([C@]([C@]1O)O)O[C@](CC(*)(*)O[C@@]([C@@]([C@]2O)O)O[C@](CO)[C@]2O)[C@]1O 0.000 description 4
- 229960000548 alemtuzumab Drugs 0.000 description 2
- 229950008085 figitumumab Drugs 0.000 description 2
- 229960000578 gemtuzumab Drugs 0.000 description 2
- 229960001972 panitumumab Drugs 0.000 description 2
- 229950010966 patritumab Drugs 0.000 description 2
- 229960004641 rituximab Drugs 0.000 description 2
- 229960005267 tositumomab Drugs 0.000 description 2
- 229960000397 bevacizumab Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229950002756 depatuxizumab Drugs 0.000 description 1
- 229950004896 ganitumab Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662431362P | 2016-12-07 | 2016-12-07 | |
| US62/431,362 | 2016-12-07 | ||
| PCT/US2017/064631 WO2018106645A1 (en) | 2016-12-07 | 2017-12-05 | β-1,6-GLUCAN THERAPEUTIC ANTIBODY CONJUGATES |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020510622A JP2020510622A (ja) | 2020-04-09 |
| JP2020510622A5 true JP2020510622A5 (https=) | 2021-02-18 |
| JP7254350B2 JP7254350B2 (ja) | 2023-04-10 |
Family
ID=62492341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019531127A Active JP7254350B2 (ja) | 2016-12-07 | 2017-12-05 | β－１，６－グルカン治療用抗体コンジュゲート |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US11865135B2 (https=) |
| EP (1) | EP3582810A4 (https=) |
| JP (1) | JP7254350B2 (https=) |
| WO (1) | WO2018106645A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018106645A1 (en) | 2016-12-07 | 2018-06-14 | Innate Biotherapeutics, Llc | β-1,6-GLUCAN THERAPEUTIC ANTIBODY CONJUGATES |
| CN113512116B (zh) * | 2020-04-10 | 2022-09-20 | 苏州普乐康医药科技有限公司 | 一种抗igf-1r抗体及其应用 |
| JP2024539993A (ja) * | 2021-10-29 | 2024-10-31 | ボルト バイオセラピューティクス、インコーポレーテッド | システイン変異抗体を含むｔｌｒアゴニスト免疫複合体、及びその使用 |
| EP4486389A1 (en) * | 2022-02-28 | 2025-01-08 | Tridem Bioscience GmbH & Co KG | A conjugate comprising at least a beta-glucan |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8883760B2 (en) | 2002-09-04 | 2014-11-11 | University Of Louisville Research Foundation, Inc. | Cancer therapy using beta glucan and antibodies |
| US8048432B2 (en) * | 2003-08-06 | 2011-11-01 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Polysaccharide-protein conjugate vaccines |
| US7070778B2 (en) | 2003-10-30 | 2006-07-04 | Laboratoire Goemar Sa | Therapeutical combination against cancer |
| JP2011519049A (ja) * | 2008-04-29 | 2011-06-30 | イミューンエクサイト インコーポレイテッド | 免疫調節組成物およびその使用方法 |
| FR2944448B1 (fr) | 2008-12-23 | 2012-01-13 | Adocia | Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes. |
| EP2461870B1 (en) | 2009-07-22 | 2017-09-06 | Biothera, Inc. | Composition comprising beta-glucan and an egf-r antibody or an egf-r antagonist for use in the treatment of kras-mutated tumors |
| US9943607B2 (en) | 2011-05-09 | 2018-04-17 | Biothera, Inc. | Beta-glucan compounds, compositions, and methods |
| EP2953976B1 (en) * | 2013-02-08 | 2021-03-24 | Novartis Ag | Specific sites for modifying antibodies to make immunoconjugates |
| CA2946679A1 (en) * | 2014-05-08 | 2015-11-12 | Immunexcite, Inc. | Immunomodulating .beta.-1,6-d-glucans |
| JP2018502123A (ja) * | 2015-01-20 | 2018-01-25 | イミューンエクサイト， インコーポレイテッド | 癌免疫療法のための組成物及び方法 |
| EP3316907A4 (en) * | 2015-06-01 | 2019-02-13 | ImmuneXcite, Inc. | CONTAINS OF BETA-1,6-GLUCAN AND ANTIBODY CÉTUXIMAB |
| WO2018106644A1 (en) | 2016-12-07 | 2018-06-14 | Innate Biotherapeutics, Llc | ß-1,6-GLUCAN TRASTUZUMAB ANTIBODY CONJUGATES |
| WO2018106645A1 (en) | 2016-12-07 | 2018-06-14 | Innate Biotherapeutics, Llc | β-1,6-GLUCAN THERAPEUTIC ANTIBODY CONJUGATES |
-
2017
- 2017-12-05 WO PCT/US2017/064631 patent/WO2018106645A1/en not_active Ceased
- 2017-12-05 JP JP2019531127A patent/JP7254350B2/ja active Active
- 2017-12-05 EP EP17879636.3A patent/EP3582810A4/en active Pending
- 2017-12-05 US US16/466,927 patent/US11865135B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2951674T3 (es) | Anticuerpo anti-MUC1 | |
| JP2020510622A5 (https=) | ||
| JP7529654B2 (ja) | 抗ｈｅｒ２抗体－ピロロベンゾジアゼピン誘導体コンジュゲート | |
| JP2021510710A5 (https=) | ||
| JP2020523413A (ja) | 操作された抗体化合物およびこれらの抱合体 | |
| JP2009539403A5 (https=) | ||
| JP2022519273A5 (https=) | ||
| JP2016536342A5 (https=) | ||
| CN114127117B (zh) | 用于偶联的多肽复合物及其应用 | |
| JP2020500834A5 (https=) | ||
| JP2024501894A5 (https=) | ||
| JP2017521054A5 (https=) | ||
| JP2021518435A (ja) | 治療用ツールとしての精密なグリココンジュゲート | |
| JP2023544143A5 (https=) | ||
| JP2018528759A5 (https=) | ||
| JP2022523360A5 (https=) | ||
| CN111247173A (zh) | 抗msln抗体及包含其的用于癌症治疗的药物组合物 | |
| CA3218663A1 (en) | Use of her2-targeting antibody-drug conjugate in treatment of her2-low expressing breast cancer | |
| JP2025512953A5 (https=) | ||
| JP7254350B2 (ja) | β－１，６－グルカン治療用抗体コンジュゲート | |
| WO2018069851A2 (en) | C-met antibody drug conjugate | |
| CN107789631B (zh) | 抗人ErbB2双表位抗体-药物偶联物及其应用 | |
| JP7276855B2 (ja) | 抗硫酸化グリコサミノグリカン抗体 | |
| JP2024543828A5 (https=) | ||
| US20210353763A1 (en) | Site-specific covalent chemical ligation to monoclonal and polyclonal immunoglobulin |